Latacomp

Timolol maleate, the active ingredient in Latacomp, is a beta‑blocker/prostaglandin analog combination presented as eye drops for ocular use. It treats open‑angle glaucoma and ocular hypertension by lowering intra‑ocular pressure. GNH USA supplies Latacomp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latacomp is used in ophthalmology to manage conditions that require reduction of intra‑ocular pressure. - Open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage. - Ocular hypertension: reduces pressure to lower the risk of progression to glaucoma. - Post‑surgical pressure control: helps maintain target pressure after glaucoma surgery.

Adverse reactions may occur with the use of Latacomp.

Common Side Effects: - Eye irritation: mild burning or stinging after instillation. - Blurred vision: temporary visual disturbance. - Eye redness: conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual pigmentation change. - Foreign body sensation: feeling of something in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Worsening glaucoma: unexpected rise in intra‑ocular pressure. - Ocular inflammation: uveitis or keratitis. - Systemic bradycardia: slowed heart rate. - Hypotension: notable drop in blood pressure. - Stevens‑Johnson syndrome: rare but serious skin reaction.

Before using Latacomp, consider the following safety measures. - Pregnancy: consult a healthcare provider as safety has not been established. - Breastfeeding: avoid unless benefits outweigh potential risks. - Cardiovascular disease: monitor heart rate and blood pressure regularly. - Respiratory disease: use with caution in patients with asthma or COPD. - Drug interactions: avoid concomitant non‑selective beta‑blockers. - Store at room temperature: keep in the original container, protect from light and moisture.

Latacomp may interact with other medications; review the following categories.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive systemic beta‑blockade. - Calcium channel blockers: may enhance hypotensive effect. - MAO inhibitors: increased risk of bradycardia. - Other prostaglandin analogs: risk of additive ocular effects.

Moderate Interactions (Monitor Closely): - Systemic antihypertensives: monitor blood pressure. - Bronchodilators: watch for bronchospasm. - Topical ocular anesthetics: may increase corneal toxicity.